TY - JOUR
T1 - The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-α enhance hypercalcemia in vivo and bone resorption in vitro
AU - Guise, Theresa A.
AU - Yoneda, Toshiyuki
AU - Yates, A. John
AU - Mundy, Gregory R.
PY - 1993/7
Y1 - 1993/7
N2 - Humoral hypercalcemia of malignancy is a multifactorial syndrome caused by the action of tumor-produced factors on target organs of bone, kidney, and intestine to disrupt normal calcium homeostasis. Although parathyroid hormone-related protein (PTHrP) plays an integral role in the syndrome, tumors also produce other hypercalcemic factors, such as transforming growth factor-α (TGF-α), which may modulate the effects of PTHrP. In order to determine if the effects of PTHrP on calcium homeostasis can be modulated by TGF-α, we have used a human squamous cell carcinoma cell line (RWGT2) which produces PTHrP alone and Chinese hamster ovarian (CHO) cells expressing only transfected human TGF-α complementary DNA (CHO/TGF-α). We studied the effects of these tumors on calcium homeostasis in nude mice bearing both tumors or each tumor alone. Whole blood ionized calcium concentrations (mean ± SEM in mmol/L) were significantly higher in mice bearing both RWGT2 and CHO/TGF-α tumors (3.11 ± 0.06, P < 0.05) when compared with mice bearing either RWGT2 alone (2.02 ± 0.06), CHO/TGF-α alone (1.42 ± 0.01), or RWGT2 and nontransfected CHO tumors (1.86 ± 0.01). This enhanced effect was also observed using continuous PTHrP-(1-34) infusion (2 micrograms/day) in mice bearing CHO/TGF-α tumors. In addition, tumor cell conditioned media was tested for bone resorbing activity in organ cultures of fetal rat long bones previously incorporated with 45cal (45Ca++). Conditioned medium at 0.1% (vol/vol) from either RWGT2 or CHO/TGF-α had no bone resorbing activity over control (%45Ca++ release, mean ± SEM; control 23 ± RWGT2 19 ± CHO/TGF-α 23 ± 1). However, the combination of 0.1% conditioned medium from RWGT2 and CHO/TGF-α significantly increased bone resorption (53 ± 2, P < 0.05). These data demonstrate that the hypercalcemic effects of tumor-produced PTHrP are enhanced by TGF-α and that this effect may be due to increased bone resorption.
AB - Humoral hypercalcemia of malignancy is a multifactorial syndrome caused by the action of tumor-produced factors on target organs of bone, kidney, and intestine to disrupt normal calcium homeostasis. Although parathyroid hormone-related protein (PTHrP) plays an integral role in the syndrome, tumors also produce other hypercalcemic factors, such as transforming growth factor-α (TGF-α), which may modulate the effects of PTHrP. In order to determine if the effects of PTHrP on calcium homeostasis can be modulated by TGF-α, we have used a human squamous cell carcinoma cell line (RWGT2) which produces PTHrP alone and Chinese hamster ovarian (CHO) cells expressing only transfected human TGF-α complementary DNA (CHO/TGF-α). We studied the effects of these tumors on calcium homeostasis in nude mice bearing both tumors or each tumor alone. Whole blood ionized calcium concentrations (mean ± SEM in mmol/L) were significantly higher in mice bearing both RWGT2 and CHO/TGF-α tumors (3.11 ± 0.06, P < 0.05) when compared with mice bearing either RWGT2 alone (2.02 ± 0.06), CHO/TGF-α alone (1.42 ± 0.01), or RWGT2 and nontransfected CHO tumors (1.86 ± 0.01). This enhanced effect was also observed using continuous PTHrP-(1-34) infusion (2 micrograms/day) in mice bearing CHO/TGF-α tumors. In addition, tumor cell conditioned media was tested for bone resorbing activity in organ cultures of fetal rat long bones previously incorporated with 45cal (45Ca++). Conditioned medium at 0.1% (vol/vol) from either RWGT2 or CHO/TGF-α had no bone resorbing activity over control (%45Ca++ release, mean ± SEM; control 23 ± RWGT2 19 ± CHO/TGF-α 23 ± 1). However, the combination of 0.1% conditioned medium from RWGT2 and CHO/TGF-α significantly increased bone resorption (53 ± 2, P < 0.05). These data demonstrate that the hypercalcemic effects of tumor-produced PTHrP are enhanced by TGF-α and that this effect may be due to increased bone resorption.
UR - http://www.scopus.com/inward/record.url?scp=0027293701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027293701&partnerID=8YFLogxK
U2 - 10.1210/jcem.77.1.8325957
DO - 10.1210/jcem.77.1.8325957
M3 - Article
C2 - 8325957
AN - SCOPUS:0027293701
SN - 0021-972X
VL - 77
SP - 40
EP - 45
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 1
ER -